DDInter788 DDInter1376
Frovatriptan is a triptan drug developed by Vernalis for the treatment of migraine headaches, in particular those associated with menstruation. Frovatriptan causes vasoconstriction of arteries and veins that supply blood to the head.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Frovatriptan {u} (Compound) binds {v} (Gene) HTR1D
Frovatriptan {u} (Compound) palliates {v} (Disease) migraine
Frovatriptan {u} (Compound) is included by {v} (Pharmacologic Class) Serotonin 1b Receptor Agonists
Frovatriptan {u} (Compound) causes {v} (Side Effect) Affect lability
Frovatriptan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vemurafenib
Frovatriptan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Morphine
Frovatriptan {u} may lead to a major life threatening interaction when taken with {v} Procarbazine
Frovatriptan {u} may lead to a major life threatening interaction when taken with {v} Palonosetron
Frovatriptan (Compound) binds HTR1D (Gene)
Frovatriptan (Compound) palliates migraine (Disease)
Frovatriptan (Compound) is included by Serotonin 1b Receptor Agonists (Pharmacologic Class)
Frovatriptan (Compound) causes Affect lability (Side Effect)
Frovatriptan may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Frovatriptan may cause a moderate interaction that could exacerbate diseases when taken with Morphine
Frovatriptan may lead to a major life threatening interaction when taken with Procarbazine
Frovatriptan may lead to a major life threatening interaction when taken with Palonosetron